FDA approves first postpartum depression drug

For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians. The FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth. CNN's Dr. Sanjay Gupta reports.

Posted: Mar 20, 2019 8:37 AM


For the first time in history, the US Food and Drug Administration has approved a drug specifically indicated for the treatment of postpartum depression, which experts say offers new hope to women and physicians.

On Tuesday, the FDA announced the approval of an intravenous infusion of the drug brexanolone, which will be sold as Zulresso. It has been shown in clinical trials to work within hours to treat the symptoms of postpartum depression, a serious mental illness that impacts 1 in 9 new mothers after childbirth.

The treatment is administered as a single 60-hour IV drip and was found to have mild side effects, such as headache, dizziness or excessive sleepiness. Yet some women may face barriers accessing this type of treatment, as it requires 60 hours of time. The drug will likely be priced around $20,000 to $35,000 per treatment, Sage Therapeutics, the company that developed the drug, confirmed.

The initial list price for Zulresso in the United States will be $7,450 per vial, resulting in a projected average course of therapy cost of $34,000 per patient before discounts, according to the company. The actual number of vials used before discounts can vary from patient to patient.

The medication will be available in June, said Dr. Jeff Jonas, CEO of the Massachusetts-based biopharmaceutical company that developed the drug. The drug will be available only through a restricted program called the Zulresso Risk Evaluation and Mitigation Strategy (REMS) Program that requires the drug be administered by a health care provider in a certified health care facility, the FDA said in a news release announcing the approval.

"There are no FDA approved antidepressants for postpartum depression, so approval of the first medication of its kind is a breakthrough for patients," said Dr. Kristina Deligiannidis, the director of Women's Behavioral Health at Northwell Health's Zucker Hillside Hospital in New York, who was involved in two of the drug's clinical trials as a researcher.

Without any treatment, postpartum depression can last for months or even years, according to the National Institute of Mental Health. Studies showed the brexanolone was effective regardless of when postpartum depression symptoms began.

In the United States, it's estimated that every year, more than 400,000 infants are born to mothers who are depressed. Treatment options for postpartum depression have included counseling or therapy with a mental health professional and antidepressant medications, but no antidepressant medication has been specifically FDA-approved to treat postpartum depression. Also, antidepressant medications generally don't provide an immediate relief of symptoms and may take several weeks to help.

"Brexanolone in phase II and III trials demonstrated rapid antidepressant effects," said Deligiannidis, who is also an associate professor at the Feinstein Institute for Medical Research and member of the Anxiety and Depression Association of America.

Those effects are something that Stephanie Hathaway, a Connecticut-based mother of two, knows well.

A 'breakthrough' drug gets tested

When Hathaway brought her first baby home from the hospital, she was just as excited and nervous as most new moms -- but she also experienced crying spells and troubling thoughts that she couldn't shake.

"The first two weeks I was crying excessively," Hathaway said. At first, her husband and she thought her tears were from "the baby blues," a feeling of sadness or emptiness after giving birth that goes away within a few days.

"But after that I had intrusive thoughts," she said. "Those were, 'Your daughter deserves a better mom,' and 'Your husband deserves a better wife.' "

Then Hathaway knew she needed help when one day she was holding her daughter and she feared what she might do to herself once she put her baby down.

That year, in 2014, Hathaway was diagnosed with postpartum depression and was treated with traditional antidepressant medications, which she said helped "over time."

A few years later, in 2017, Hathaway had a second child, and was prescribed the same antidepressants during that pregnancy -- but the medications were not helpful in relieving her symptoms.

A friend told Hathaway about clinical trials being conducted to evaluate the effectiveness of brexanolone in treating postpartum depression. Hathaway enrolled in a trial.

"It was a 60-hour infusion and in the first 12 to 18 hours I felt the biggest difference," Hathaway said.

"Those intrusive thoughts that played on repeat in my head, those went away and didn't come back," she said, adding that as a side effect, "I just had one very small instance of standing up and feeling lightheaded."

In 2016, the FDA granted brexanolone a "breakthrough therapy designation" for the treatment of postpartum depression. Such a designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.

Results from two phase III trials of brexanolone, conducted across 30 clinical research centers and specialized psychiatric units in the United States, published in the journal The Lancet in August.

The trials, conducted in 2016 and 2017, involved more than 200 women who had symptoms of postpartum depression, which were assessed by standardized research scales. The women were followed up with over 30 days. Sage Therapeutics funded the research.

In those studies, some of the women were given 60-hour IV infusions of smaller or larger doses of brexanolone while others were given a placebo. The researchers found that the women who received brexanolone infusions had "significant and clinically meaningful" reductions in their depression scores.

In the first study, by the end of 60 hours, the average reduction was 19.5 points in the brexanolone group that received smaller doses, and 17.7 points in the brexanolone group that received larger doses, compared with 14 points in the placebo group.

In the second study, which had only one brexanolone group, the average reduction in score was by 14.6 points in the brexanolone group compared with 12.1 points in the placebo group at 60 hours, the researchers found.

Overall, at 60 hours, about 75% of women who received brexanolone were at least 50% improved in their symptoms and about half of women who received brexanolone were no longer clinically depressed, Deligiannidis said.

Among the patients who had a response at 60 hours, 94% did not relapse at the 30-day followup.

The most common side effects included headache among 15.7% of patients; dizziness among 13.6%; and somnolence or excessive sleepiness among 10.7%, the researchers found.

The researchers wrote in the study that their findings "provide strong evidence for the efficacy and safety of brexanolone injection in women with moderate to severe post-partum depression."

Limitations of the studies include that the women were followed only for 30 days, so the duration of treatment effects beyond that were not included in the data.

The treatment also requires 60 hours of an IV -- which, for women without support at home or living in poverty, could be difficult. Low-income mothers are at high risk for postpartum depression. The treatment also could interrupt breastfeeding, and patients are encouraged to discuss the risks and benefits of breastfeeding with their physician.

Additionally in the trials, brexanolone had the most robust effects on women experiencing severe postpartum depression whereas results were more modest among others whose postpartum depression was less severe.

'It potentially sets a new standard for treatment'

"What has been consistent is that brexanolone had a very robust response -- and what's been most exciting to me, in terms of participating in this new drug development, was the rapid onset of response. The drug works quickly," said Dr. Samantha Meltzer-Brody, a professor of mood and anxiety disorders at the University of North Carolina School of Medicine in Chapel Hill, who was a researcher in those phase III trials for the drug.

"My greatest hope is that this increases awareness. What's heartbreaking is the number of women who suffer in silence and do not get the treatment that they need," she said. "People need to reach out and get screened and get treatment, regardless of if treatment is with brexanolone or not."

The clinical data supporting the effectiveness of brexanolone in helping women recover from postpartum depression sheds new light on the neurobiology of the illness, as well as depression during other life periods, said Catherine Monk, professor of medical psychology in obstetrics and gynecology and psychiatry at Columbia University Irving Medical Center and director of research in the women's program in psychiatry at NewYork-Presbyterian/Columbia University Irving Medical Center in New York. Monk was not involved in the drug trials.

Monk, who is also a research scientist at the New York State Psychiatric Institute, added that "because its effects are truly expedited, within days, it potentially sets a new standard for treatment for severe postpartum depression."

Terre Haute
Cloudy
71° wxIcon
Hi: 88° Lo: 64°
Feels Like: 71°
Robinson
Cloudy
70° wxIcon
Hi: 86° Lo: 65°
Feels Like: 70°
Indianapolis
Mostly Cloudy
72° wxIcon
Hi: 89° Lo: 66°
Feels Like: 72°
Rockville
Mostly Cloudy
69° wxIcon
Hi: 89° Lo: 64°
Feels Like: 69°
Casey
Cloudy
71° wxIcon
Hi: 85° Lo: 66°
Feels Like: 71°
Brazil
Cloudy
71° wxIcon
Hi: 88° Lo: 65°
Feels Like: 71°
Marshall
Cloudy
71° wxIcon
Hi: 87° Lo: 63°
Feels Like: 71°
Mostly cloudy, scattered showers and storms.
WTHI Planner
WTHI Temps
WTHI Radar

Latest Video

Image

Local Woman's Back to School Drive

Image

Walk to End Alzheimer's

Image

Sunday Evening: Scattered showers and storms.

Image

Sunday: Increasing clouds, hot. High: 90°

Image

Saturday Evening Forecast

Image

Saturday: Mostly sunny, unseasonably warm. High: 89°

Image

Casey-Westfield

Image

Parke Heritage football

Image

Sullivan football

Image

Robinson football

WTHI Events

 

Illinois Coronavirus Cases

(Widget updates once daily at 7 p.m. CT)

Cases: 1590342

Reported Deaths: 26979
CountyCasesDeaths
Cook60937610925
DuPage1031521352
Will865801083
Lake764741056
Kane65399842
Winnebago38682543
Madison37731569
St. Clair34758561
McHenry32773313
Peoria25738361
Champaign25601182
Sangamon24263266
McLean21611205
Tazewell19559326
Rock Island17631342
Kankakee16523233
Kendall15274105
LaSalle14349275
Macon14248233
Vermilion12908182
Adams12589147
DeKalb11542127
Williamson11206156
Whiteside7813176
Boone756681
Jackson756683
Coles7175112
Ogle705385
Grundy693181
Clinton676498
Franklin669694
Knox6528163
Marion6454135
Macoupin636597
Henry610272
Jefferson5981131
Effingham588980
Livingston564394
Woodford549791
Stephenson540089
Randolph522996
Monroe503299
Christian481980
Morgan479995
Fulton479069
Logan473573
Montgomery462876
Lee454956
Bureau423087
Perry411171
Saline399263
Iroquois391171
Fayette387756
McDonough352155
Jersey319753
Douglas303336
Shelby300343
Crawford298930
Lawrence294631
Union293846
Wayne267957
White261530
Richland256852
Hancock253434
Pike252256
Cass247728
Clark244138
Bond242224
Clay233347
Ford233056
Edgar229844
Carroll223937
Warren220456
Moultrie209331
Johnson208922
Washington204927
Jo Daviess203525
Greene199339
Mason196251
Wabash196115
Massac195144
De Witt192730
Piatt188814
Mercer187035
Cumberland174123
Menard155812
Jasper149518
Marshall133721
Hamilton127221
Brown10138
Pulaski97311
Schuyler9608
Edwards94815
Stark76027
Gallatin7285
Scott6895
Alexander66411
Calhoun6382
Henderson63114
Hardin55713
Putnam5414
Pope4725
Unassigned1582432
Out of IL80

Indiana Coronavirus Cases

(Widget updates once daily at 8 p.m. ET)

Cases: 926604

Reported Deaths: 15083
CountyCasesDeaths
Marion1262201958
Lake626901087
Allen52772747
Hamilton43283445
St. Joseph41475584
Elkhart33129488
Vanderburgh29927439
Tippecanoe26589247
Johnson23267415
Hendricks21902340
Porter21473341
Clark17150224
Madison17065379
Vigo15815273
Monroe14298190
LaPorte14108237
Delaware13771219
Howard13635262
Kosciusko11232134
Hancock10637160
Warrick10523176
Bartholomew10341167
Floyd10200202
Wayne9690218
Grant8939196
Morgan8734158
Boone8299109
Dubois7596123
Henry7469128
Dearborn745187
Noble7294101
Marshall7237128
Cass7097117
Lawrence6862150
Shelby6457107
Jackson643981
Gibson6036106
Harrison595585
Huntington591891
Montgomery5706102
DeKalb563591
Knox537599
Miami531983
Clinton527164
Putnam525367
Whitley516251
Steuben486367
Wabash477492
Jasper471961
Jefferson461991
Ripley444175
Adams439365
Daviess4064106
Scott394963
White386257
Clay382356
Greene380189
Wells379683
Decatur379595
Fayette367176
Posey354941
Jennings346356
Washington325847
LaGrange315774
Spencer313034
Fountain309753
Randolph305487
Sullivan299447
Owen279161
Starke272761
Orange272659
Fulton268851
Jay250634
Perry247451
Carroll241127
Franklin233637
Vermillion229750
Rush228930
Parke215220
Tipton206754
Pike202538
Blackford165634
Pulaski158751
Crawford142818
Newton140742
Benton139816
Brown132646
Martin126916
Switzerland123510
Warren113416
Union93511
Ohio77211
Unassigned0468